Conditions: Alzheimer's Disease
Keywords: Alzheimer's Disease, Amyloid Beta, cerebrospinal fluid, beta secretase
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 124
Healthy volunteers: yes

Brief summary:
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.

Detailed description:

Arms:
arm 1: Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks. arm 2: CNP520 2 mg was taken qd orally for 13 weeks. arm 3: CNP520 10 mg was taken qd orally for 13 weeks. arm 4: CNP520 35 mg was taken qd orally for 13 weeks. arm 5: CNP520 85 mg was taken qd orally for 13 weeks.

Interventions: intervention 1: CNP520 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: Matching placebo to CNP520 was supplied in capsules.

Protocol document: